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Abstract: Serious Mental Illnesses (SMI) are psychiatric disorders 
(excluding developmental and substance use disorders) that result in 
considerable functional impairment. These conditions receive little or no 
funding in most Low and Middle Income (LAMI) countries.  The huge gap in 
resources for SMI can only be met by a global fund to provide the 
treatment of SMI in LAMI countries. The Global Fund to fight AIDS 
established more than two decades ago, not only provided enormous funding 
but most importantly, generated the hope that the condition could be 
treated. We argue that SMI stand today where HIV-AIDS was a couple of 
decades ago. The cost effective interventions for these disorders are 
available. For example, it is estimated that that an extra 11 Naira or I$ 
0.27 per capita would need to be invested each year to increase the 
present treatment coverage for schizophrenia of 20% to a level of 70% in 
Nigeria. The treatment package should include free access to essential 
medicines to treat psychotic disorders and a component of appropriate 
evidence based psychosocial intervention, which have been evaluated in 
number of studies in these countries. It is ethical and public health 
imperative that a Global Fund to provide the basic treatment for those 
suffering from SMI is established and the seed money for the proposed 
fund should be provided by rapidly developing LAMI countries such as 
India and South Africa. 
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Manuscrip CLEARt
 The economic, social and human costs of Serious Mnetal Ilness (SMI), defined as psychiatric 
disorders (excluding developmental and substance dependence) which radically interfere with one 
or more major life activities, are  well documented1.The arguments for providing access to treatment 
for these conditions in low-income and middle-income countries are also well known.  However, the 
treatment gap for SMI in most of these countries remains a major public health challenge. On 
average, patients suffering from the first episode of psychosis are likely to remain untreated for 
more than two years2. Despite the fact that the actual cost of antipsychotic treatment is quite low in 
most low-income and middle-income countries, the economic factors  remain a major barrier  in the 
lack of treatment2. Even if the patients are able to purchase antipsychotic medication, it may be at 
the expense of other forms of essential medical care or even food.  
 
The public health impact of SMI is comparable to that of many infectious and chronic physical 
illnesses that receive much more funding for both treatment and research. For example, in low-
income and middle-income economies schizophrenia results in 14.8 Millions YLDs (Years Lost due to 
Disability). As  sixth leading cause of disability this is marginally less than the cataract  (17.4 Millions 
YLD) and much greater  than Iron deficiency anaemia (12.6 Millions YLD)3. The GBD 2010 (Global 
Burden of Disease) study does not provide ranking for low income and middle income countries 
together but the situation has only become worse, as the  burden of mental and substance use 
disorders  has increased by 37.6% in 2010. 4. The public health and research funding for 
schizophrenia, however, is not even a fraction of that allocated to either of these conditions. 
 
The Global Fund to Fight AIDS, Tuberculosis and Malaria, was established  in 2002. The fund 
increased the resources available to fight these diseases, stimulated  the domestic investments in 
health  and  helped to reduce stigma5.Most importantly, the global fund generated the hope that 
these illnesses could be treated and  brought these devastating conditions in the mainstream public 
health arena. 
 
We believe that the SMI stands today where HIV-AIDS were a couple of decades ago. The case for 
establishing a similar fund for SMI  is compelling in view of the sheer size of the problem, the 
associated human rights violations, and the need to combat stigma. We challenge countries and 
multilateral agencies to establish a Global Mental Health Fund to provide free treatment for SMI in 
low-income and middle-income countries.  
The provision of free basic treatment for SMI in these countries has been shown to be feasible and 
economically viable. For example,  in schizophrenia, the most cost-effective interventions are those 
using first-generation antipsychotic drugs combined with psychosocial treatment, and delivered via a 
community-based service model6. It is calculated that to increase the present treatment coverage of 
20% to a coverage of 70% in Nigeria would require an extra 11 Naira or I$ 0.27 per capita.7 These 
estimates are based on first-generation antipsychotics.  Most second generation antipsychotics, 
recommended by many treatment guidelines, have also become generic which has reduced costs 
considerably.  
A major challenge in low-income and middle-income countries is the shortage of specialist mental 
health professionals. Non-specialist health workers are  effective in improving outcomes in 
psychiatric disorders  and  supervised community health workers have been successfully employed 
in providing community-based treatments for  moderate to severe schizophrenia8. Research is also 
providing evidence for the efficacy of psychoeducational strategies to improve treatment adherence, 
to decrease relapse rates and to have positive impact on social functioning9,10  
Like AIDS, treatment for SMI is required for extended periods of time. However, the appropriate 
management of SMI does not require expensive diagnostics and in most cases, the drug costs are 
relatively low. The mhGAP initiative of the World Health Organization ( 
http://www.who.int/mental_health/mhgap/en/) is integrating existing evidence into appropriate, 
cost-effective packages of care – thus we largely already know what is needed.  
We suggest that low-income and middle-income countries such as India, Brazil, South Africa and 
China take the lead in providing the seed money to establish such a fund.  It is estimated that about 
41.7 million people need treatment for schizophrenia and related disorders in these countries. The 
majority of  cases is concentrated in Asia (70%) and Africa (16%) 11. It is therefore an ethical 
imperative for these countries to take a leading role in such an effort.  
 
The treatment package should include free access to essential medicines to treat psychotic disorders 
and a component of appropriate psychosocial intervention. At the very least, it may be possible to 
provide such a treatment package during the initial two to three years after the onset of psychosis. 
This will help to prevent significant disability and possibly higher mortality as there is  compelling 
evidence that untreated illness during this critical period can result  in long term disability and higher 
mortality in such contexts12.  The early intervention services to treat the  first episode of the illness 
during this critical period of illness are now well established way of imrproving outcomes.  
 
Such a global initiative would likely prove to be an effective anti-poverty measure, as there is 
compelling evidence that lack of treatment for SMI leads to a vicious cycle of poverty both for 
patients and extendedfamilies(  http://www.who.int/mental_health/policy/development/en/). Most 
importantly, perhaps, such a global fund, even at a limited scale, would help to put mental health on 
the public health agenda, the lack of which  is a key barrier to service development.    
 
Authors contributions, conflict of interest and funding:  SF conceived the idea and wrote 
the first draft. JB, AS and FN contributed equally to the final draft of the article. Authors 
have no conflict of interest to declare. The ethics approval was not required. There is no 
funding involved in writing of this article. 
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*Manuscript with revisions highlighted
 The economic, social and human costs of Serious Mnetal Ilness (SMI), defined as psychiatric 
disorders (excluding developmental and substance dependence) which radically interfere with one 
or more major life activities1, are  well documented.21 The arguments for providing access to 
treatment for these conditions in low-income and middle-income countries are also well known. 
rehearsed/3 However, the treatment gap for SMI in most of these countries remains a major public 
health challenge. On average, patients suffering from the first episode of psychosis are likely to 
remain untreated for more than two years24. Despite the fact that the actual cost of antipsychotic 
treatment is quite low in most low-income and middle-income countries, the economic factors are 
frequently reported as a major barrier  in the lack of treatment42. Even if the patients are able to 
purchase antipsychotic medication, it may be at the expense of other forms of essential medical care 
or even food.  
 
The public health impact of SMI is comparable to that of many infectious and chronic physical 
illnesses that receive much more funding for both treatment and research. For example, in low-
income and middle-income economies schizophrenia results in 14.8 Millions YLDs (Years Lost due to 
Disability). As  sixth leading cause of disability this is marginally less than the cataract  (17.4 Millions 
YLD) and much greater  than Iron deficiency anaemia (12.,6 Millions YLD)53. The GBD 2010 (Global 
Burden of Disease) study does not provide ranking for low income and middle income countries 
together but the situation has only become worse as the  burden of mental and substance use 
disorders  has increased by 37.6% in 2010. 4. The publice health and research funding for 
schizophrenia, however, is not even a fraction of that allocated to either of these conditions. 
 
The Global Fund to Fight AIDS, Tuberculosis and Malaria, was established  in 2002. The fund 
increased the resources available to fight these diseases, stimulated  the domestic investments in 
health  and  helped to reduce stigma.65 Most importantly, the global fund generated the hope that 
these illnesses could be treated and  brought these devastating conditions in the mainstream public 
health arena. 
 
We believe that the SMI stands today where HIV-AIDS were a couple of decades ago. The case for 
establishing a similar fund for SMI  is compelling in view of the sheer size of the problem, the 
associated human rights violations, and the need to combat stigma. We challenge countries and 
multilateral agencies to establish a Global Mental Health Fund to provide free treatment for SMI in 
low-income and middle-income countries.  
The provision of free basic treatment for SMI in these countries has been shown to be feasible and 
economically viable. For example,  in schizophrenia, the most cost-effective interventions are those 
using first-generation antipsychotic drugs combined with psychosocial treatment, and delivered via a 
community-based service model76. It is calculated that to increase the present treatment coverage 
of 20% to a coverage of 70% in Nigeria would require an extra 11 Naira or I$ 0.27 per capita.87 These 
estimates are based on first-generation antipsychotics.  Most second generation antipsychotics, 
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recommended by many treatment guidelines, have also become generic which has reduced costs 
considerably.  
A major challenge in low-income and middle-income countries is the shortage of specialist mental 
health professionals. Non-specialist health workers are  have been shown be effective in improving 
outcomes in psychiatric disorders  and  supervised community health workers have been 
successfully employed in providing community-based treatments for  moderate to severe 
schizophrenia798. Research is also providing evidence for the efficacy of psychoeducational 
strategies to improve treatment adherence, to decrease relapse rates and to have positive impact on 
social functioning10,119,10  
Like AIDS, treatment for SMI is required for extended periods of time. However, the appropriate 
management of SMI does not require expensive diagnostics and in most cases, the drug costs are 
relatively low. The mhGAP initiative of the World Health Organization ( 
http://www.who.int/mental_health/mhgap/en/) 12 has already begun integrating existing evidence 
into appropriate, cost-effective packages of care – thus we largely already know what is needed.  
We suggest that low-income and middle-income countries such as India, Brazil, South Africa and 
China take the lead in providing the seed money to establish such a fund.  It is estimated that about 
41.7 million people need treatment for schizophrenia and related disorders in these countries. The 
majority of  cases is concentrated in Asia (70%) and Africa (16%) 1311. It is therefore an ethical 
imperative for these countries to take a leading role in such an effort.  
 
The treatment package should include free access to essential medicines to treat psychotic disorders 
and a component of appropriate psychosocial intervention. At the very least, it may be possible to 
provide such a treatment package during the initial two to three years after the onset of psychosis. 
This will help to prevent significant disability and possibly higher mortality as there is  compelling 
evidence that untreated illness during this critical period can result  in long term disability and higher 
mortality in such contexts1412.  The early intervention services to treat the  first episode of the 
illness during this critical period of illness are now well established way of imrproving outcomes.  
 
Such a global initiative would likely prove to be an effective anti-poverty measure, as there is 
compelling evidence that lack of treatment for SMI leads to a vicious cycle of poverty both for 
patients and extended families15(  http://www.who.int/mental_health/policy/development/en/). . 
Most importantly, perhaps, such a global fund, even at a limited scale, would help to put mental 
health on the public health agenda, the lack of which  is a key barrier to service development.    
 
Authors contributions, conflict of interest and funding:  SF conceived the idea and wrote 
the first draft. JB, AS and FN contributed equally to the final draft of the article. Authors 
have no conflict of interest to declare. The ethics approval was not required. There is no 
funding involved in writing of this article. 
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Dear Joan 
Re: 2
nd
 resubmission Manuscript reference number: THELANCETPSYCH-D-16-00060 
 
Title: A Global Mental Health Fund for the treatment of Serious Mental Illness in Low 
Income and Middle Income Countries 
 
 
Thank you for considering and accepting this manuscript, I have again  revised the paper in 
the light of your comments. The draft with Track Changes and a clear version with all 
changes accepted, are submitted. Following changes have been made. Your comments are 
highlighted in red. 
The number of references is now 12.  I agree that reference 1&  2 can be omitted as  these  
cover points which are well  known to the  specialist readers. This has necessitated minor 
changes in the text.  Another reference is added to cite the GBD 2010 study but after deleting 
four references from previous version, the number of total references is 12. There are minor 
edits.  The total words are no 898.  
   
Reference 5 is to data from 2004. The latest GBD figures are from 2013 though I'm not sure 
whether they include economic costs. Please can you check that you have the most current 
available data for this?   
I spent considerable time on finding the relevant figures in GBD10 study. The GBD 2010 
does not provide the comparisons mentioned in our draft in its tool ‘GBD Compare’ 
(http://vizhub.healthdata.org/gbd-compare/). I have added a sentence to this effect in the 
paragraph 2 and provided GBD 2010 reference.     
 
As advised the WHO references (12 and 15 in previous version) are now included in 
parentheses and removed from the reference list. 
 
I have checked the current reference 13 (now reference No. 11).  This is correct.  
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